ING Belgium, Petercam are bookrunners; deal funds product development
By Devika Patel
Knoxville, Tenn., June 29 - MDxHealth SA said it priced a €10 million private placement of shares. The offering was announced Thursday.
The company will sell 6,891,113 ordinary shares. Of the shares, 1,996,008 will be sold to Biovest Comm. VA at €1.503 per share, which is a 5.11% premium to the June 28 closing share price of €1.43. The remaining 4,895,105 shares will be sold to other investors at €1.43 per share, identical to the June 28 closing share price.
ING Belgium NV/SA and Petercam NV/SA are joint bookrunners.
Settlement is expected July 4.
Proceeds will be used to support and scale-up a U.S.-based sales and marketing team, operate and scale-up the company's U.S.-based CLIA-registered commercial laboratory and accelerate product development.
MDxHealth is a Liege, Belgium, molecular diagnostics company.
| Issuer: | MDxHealth SA
|
| Issue: | Ordinary shares
|
| Amount: | €10 million
|
| Shares: | 6,891,113
|
| Price: | €1.503 (for 1,996,008 shares), €1.43 (for 4,895,105 shares)
|
| Warrants: | No
|
| Bookrunners: | ING Belgium NV/SA and Petercam NV/SA
|
| Investor: | Biovest Comm. VA (for €3 million)
|
| Announcement date: | June 28
|
| Pricing date: | June 29
|
| Settlement date: | July 4
|
| Stock symbol: | Brussels: MDXH
|
| Stock price: | €1.43 at close June 28
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
